Elite Journal of HIV. Volume 2 issue 1(2024), Pp. 1-15
https://epjournals.com/journals/EJHIV

Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues

*Emmanuel Ifeanyi Obeagu[1], Arinze Favour Anyiam [2] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]Department of Medical Laboratory Science, School of Basic Medical and Health Sciences, Igbinedion University, Okada, Edo State, Nigeria.
School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Human Immunodeficiency Virus (HIV) poses a significant global health challenge, necessitating a deeper comprehension of the immune responses engaged in infection. B cell mediated immunity emerges as a pivotal aspect in the battle against HIV, with this review aiming to elucidate the intricacies of antibody responses, viral escape mechanisms, and their implications for vaccine development. Recent breakthroughs and therapeutic avenues are explored, alongside the persisting challenges that underscore the complexity of HIV immunology. This review consolidates current knowledge to provide a holistic understanding of B cell mediated immunity in HIV infection, offering insights that may shape future research endeavors and therapeutic strategies.

Keywords*: HIV, B cell mediated immunity, antibodies, viral escape, vaccine development, humoral response, immunopathogenesis*

Introduction

Human Immunodeficiency Virus (HIV) remains a formidable global health concern, affecting millions of individuals worldwide. Despite significant strides in understanding and managing the virus, the quest for effective therapeutic interventions and preventive strategies continues. Among the diverse components of the immune system involved in the response against HIV, B cells have emerged as crucial players in orchestrating humoral immunity. This introduction sets the stage for a comprehensive exploration of the role of B cell mediated immunity in the context of HIV infection, aiming to unravel the complexities surrounding antibody responses, viral escape mechanisms, and their implications for vaccine development.[1-13] The HIV pandemic has spurred

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

extensive research efforts to decipher the intricate interactions between the virus and the host immune system. B cells, traditionally recognized for their role in antibody production, play a multifaceted role in the ongoing battle against HIV. Understanding the dynamics of B cell responses is paramount, as it not only informs our comprehension of immunopathogenesis but also guides the development of innovative therapeutic approaches.[14-20]

This review embarks on a journey to unravel the nuances of B cell mediated immunity in the context of HIV infection. By delving into the mechanisms of antibody responses, exploring the challenges posed by viral escape, and examining the implications for vaccine development, we aim to provide a comprehensive overview of the current state of knowledge. Furthermore, we will explore recent breakthroughs and potential therapeutic avenues, recognizing the dynamic landscape of HIV research and the evolving strategies to combat the virus. As the world grapples with the ongoing HIV pandemic, a deeper understanding of B cell mediated immunity is essential for the development of targeted and effective interventions. By shedding light on the intricacies of this immune response, we hope to contribute to the collective effort to advance our knowledge and pave the way for improved strategies in the prevention, treatment, and management of HIV infection.

Antibody Responses in HIV

The humoral immune response, orchestrated by B cells, constitutes a critical line of defense against HIV infection. Understanding the dynamics of antibody responses is pivotal for unraveling the complexities of the host-virus interaction and guiding the development of effective therapeutic strategies. In the initial stages of HIV infection, a rapid and robust antibody response is triggered. Non-neutralizing antibodies are typically the first to appear, targeting various viral proteins. However, these antibodies often fail to confer sufficient protection, and the virus rapidly evolves to escape their recognition. A subset of individuals infected with HIV eventually develops broadly neutralizing antibodies (bNAbs) capable of recognizing diverse viral strains. The identification and characterization of bNAbs have been significant milestones, offering insights into conserved epitopes on the viral envelope. Despite their potency, inducing these antibodies through vaccination remains a formidable challenge.[21-35]

The induction of bNAbs is hindered by the virus's ability to rapidly mutate and evade immune recognition. This section explores the hurdles in eliciting and sustaining broadly neutralizing responses, including the complex glycosylation patterns on the viral envelope and the conformational flexibility of key epitopes. Antibodies play a dual role in HIV infection, contributing not only to direct viral neutralization but also to other effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Understanding these diverse functions is crucial for harnessing the full potential of B cell mediated immunity. The ongoing arms race between the immune system and HIV is characterized

by viral escape. This section explores the mechanisms through which the virus evades antibody recognition, including the selection of escape mutations and the shielding of vulnerable epitopes. The constant evolution of the viral quasispecies poses a significant challenge for sustaining effective antibody responses. The insights gained from studying antibody responses in HIV infection have profound implications for vaccine design. Strategies to elicit durable and broadly neutralizing antibody responses are explored, including novel immunogen designs, vaccine delivery systems, and adjuvants.[36-51]

Viral Escape

One of the persistent challenges in developing effective interventions against Human Immunodeficiency Virus (HIV) lies in its remarkable capacity to evade the host immune system through viral escape mechanisms. HIV is characterized by a high mutation rate and the generation of diverse viral quasispecies within an infected individual. This genetic diversity enables the virus to adapt rapidly to selective pressures, including those imposed by the host's immune responses. As a result, the virus continually evolves, presenting a moving target for B cell recognition. The virus employs a selective pressure strategy to escape neutralization by antibodies. This involves the emergence of mutations in key viral epitopes targeted by antibodies, rendering them less effective or entirely evading recognition. The ongoing arms race between the immune system and the virus drives the selection of these escape variants. The HIV envelope glycoprotein (Env) is heavily glycosylated, forming a protective shield that masks vulnerable epitopes. Additionally, the conformational flexibility of Env allows the virus to undergo structural changes, further evading antibody recognition. Understanding these mechanisms is crucial for devising strategies to overcome the challenges posed by the viral glycan shield.[52-64]

HIV can evolve independently within distinct anatomical compartments, such as the blood and lymphoid tissues. This compartmentalization contributes to the diverse viral populations observed in different tissues, complicating the development of immune responses that effectively target the entire viral quasispecies. The constant viral escape poses a formidable barrier to the development of an effective HIV vaccine. Strategies to induce broadly neutralizing antibodies must account for the virus's ability to rapidly adapt and escape immune recognition. This section explores ongoing research efforts to design vaccines that can anticipate and counteract viral escape mechanisms. The understanding of viral escape mechanisms has direct implications for therapeutic interventions. Antiretroviral therapies (ART) have been successful in controlling viral replication, but the emergence of drug-resistant strains underscores the need for continued research into novel therapeutic approaches that can effectively target evolving viral variants.[65-75]

Implications for Vaccine Development

The perpetual challenge of viral escape in Human Immunodeficiency Virus (HIV) infection significantly influences the landscape of vaccine development. As B cell mediated immunity forms a cornerstone of the host's defense against the virus, understanding the implications of viral escape

is paramount for devising effective vaccine strategies. The constant evolution of the HIV quasispecies demands a vaccine approach that can anticipate and counteract diverse viral variants. The traditional vaccine paradigm of inducing a sterilizing immune response faces challenges due to the dynamic nature of the virus, necessitating innovative strategies that can cope with the adaptability of HIV. Despite the challenges, the identification and characterization of broadly neutralizing antibodies (bNAbs) provide a beacon of hope for vaccine development. Efforts to elicit these potent antibodies through vaccination aim to confer broad protection against diverse HIV strains. This section explores the progress, challenges, and potential breakthroughs in inducing bNAbs as a central component of an effective HIV vaccine.[76-84]

Advancements in structural vaccinology enable researchers to design vaccines that precisely target conserved regions of the viral envelope. By focusing on vulnerable epitopes and leveraging structural information, vaccine development efforts aim to induce immune responses that are resilient to viral escape. Prime-boost vaccination approaches, involving the sequential administration of different vaccine components, aim to enhance and prolong the immune response. Strategies combining various viral vectors, protein subunits, and adjuvants are under investigation to optimize B cell mediated immunity. Recognizing the individualized nature of immune responses and the diversity of viral quasispecies among patients, personalized vaccination approaches are gaining attention. Tailoring vaccines to an individual's viral variants may enhance the likelihood of inducing effective and durable B cell responses. Vaccine development must not solely focus on inducing neutralizing antibodies but also consider other facets of the immune response, including cell-mediated immunity and non-neutralizing antibody functions. A comprehensive approach may provide a more resilient defense against the virus.[85-86]

B Cell Immunotherapy Approaches

Harnessing the potential of B cell mediated immunity in the fight against Human Immunodeficiency Virus (HIV) extends beyond traditional vaccination strategies. B cell immunotherapy approaches have gained prominence as innovative interventions, exploring various techniques to enhance and manipulate the immune response. Monoclonal antibodies, particularly those with broadly neutralizing properties, have shown promise in suppressing viral replication and controlling HIV infection.[87] Targeting B cells directly, therapies involving B cell depletion have been explored for their potential impact on HIV reservoirs. While this approach poses challenges in terms of maintaining protective antibody responses, reactivating latent B cells may contribute to controlling viral replication. Engineering B cell receptors to enhance their specificity and affinity for HIV antigens represents a cutting-edge approach. Adoptive transfer of engineered or ex vivo-expanded B cells aims to bolster the host's immune response against HIV. Recognizing the complexity of HIV infection, combination therapies involving B cell immunotherapy alongside other modalities, such as antiretroviral drugs and immune checkpoint inhibitors, are under investigation. Modulating the immune system to enhance B cell responses against HIV involves the use of immunomodulatory agents.

Immunopathogenesis: Balancing Act

The intricate dance between the human immune system and Human Immunodeficiency Virus (HIV) during the course of infection is a dynamic process that shapes the immunopathogenesis of the disease. In the initial stages of HIV infection, the immune system mounts a robust response to control viral replication. However, this early immune activation can lead to persistent inflammation. CD4+ T cells, the primary targets of HIV, play a central role in orchestrating immune responses. The progressive depletion of these cells compromises the immune system's ability to mount effective responses. B cells, integral to the humoral arm of the immune system, are directly impacted by HIV infection. The virus can dysregulate B cell function, leading to aberrant antibody production and impaired antigen presentation. The intricate network of cytokines plays a pivotal role in mediating immune responses. HIV infection disrupts the delicate balance of cytokine production, leading to dysregulation and chronic immune activation.[88]

Persistent inflammation, a hallmark of chronic HIV infection, contributes to end-organ damage. The virus induces a state of heightened immune activation that may lead to complications such as cardiovascular disease, neurocognitive disorders, and accelerated aging. As HIV progresses, the balance tips towards immunosuppression, rendering individuals susceptible to opportunistic infections. Recognizing the delicate balance between immune activation and immunosuppression has direct implications for therapeutic interventions. Antiretroviral therapies (ART) aim to control viral replication and mitigate immune dysfunction. However, achieving a fine-tuned balance in restoring immune homeostasis remains a complex challenge. The evolving field of precision medicine holds promise in tailoring therapeutic approaches to individual immune profiles. Understanding the immunopathogenesis on a personalized level may pave the way for targeted interventions that optimize immune responses and minimize adverse effects.[89]

Challenges and Future Directions

Despite significant progress in understanding Human Immunodeficiency Virus (HIV) and developing therapeutic strategies, numerous challenges persist, necessitating continued research and innovation. A major obstacle in HIV eradication is the establishment of long-lived viral reservoirs, even in individuals on successful antiretroviral therapy (ART). The identification and elimination of these reservoirs pose significant challenges. Future research should focus on developing strategies to target and eliminate latent viral reservoirs, moving closer to a functional cure for HIV. Designing an effective HIV vaccine remains an ongoing challenge due to the virus's ability to rapidly mutate, escape immune recognition, and establish diverse quasispecies. Future directions in vaccine development should explore novel immunogen designs, innovative delivery systems, and adjuvants to induce potent and broad immune responses. Collaborative efforts and data sharing will be crucial for advancing vaccine research.

The continuous evolution of HIV and its intricate immune evasion strategies necessitate a deeper understanding of viral-host interactions. Future research should focus on deciphering the

mechanisms employed by the virus to escape immune surveillance, enabling the development of targeted interventions to counteract these evasion strategies. Host genetics play a significant role in determining the outcome of HIV infection and the response to treatment. Future directions should include exploring the influence of host genetic factors on susceptibility, disease progression, and treatment outcomes. Personalized or individualized therapeutic approaches based on host genetic profiles could optimize treatment efficacy. Despite advancements in treatment, access to antiretroviral therapies remains a challenge in many regions, contributing to healthcare disparities. Future efforts should focus on improving global access to HIV treatment, addressing social determinants of health, and implementing strategies to reduce disparities in HIV care.

HIV often coexists with other infections and comorbidities, leading to complex clinical scenarios. Future research should explore the interactions between HIV and co-infections, such as tuberculosis and viral hepatitis, as well as the impact of long-term HIV infection on aging-related comorbidities. Understanding these interactions is vital for comprehensive patient care.[40] Stigma and discrimination continue to be significant barriers to HIV prevention, testing, and treatment. Future efforts should prioritize destigmatization campaigns, education, and community engagement to create an inclusive environment that encourages testing, treatment adherence, and overall well-being for individuals living with HIV. Developing novel approaches for HIV prevention, such as long-acting antiretrovirals, pre-exposure prophylaxis (PrEP) optimization, and alternative delivery methods, is essential. Future directions should explore innovative prevention strategies to broaden the range of options available and increase their accessibility. Harnessing technological advancements, such as artificial intelligence, big data analytics, and telemedicine, can enhance HIV research, diagnosis, and treatment. Future directions should explore the integration of technology to optimize healthcare delivery, improve patient outcomes, and streamline research processes.

Conclusion

The role of B cells in HIV infection extends beyond antibody production, encompassing a dynamic interplay with the virus that shapes the course of the immune response. Understanding the nuances of B cell mediated immunity is essential for devising effective preventive and therapeutic strategies. The adaptability of HIV through viral escape mechanisms presents a formidable challenge, influencing vaccine development and necessitating innovative approaches. A deeper understanding of the mechanisms driving viral escape is crucial for overcoming this obstacle and achieving durable immune responses. Despite advances, developing an effective HIV vaccine remains elusive. Challenges include the rapid mutation rate of the virus, the quest for broadly neutralizing antibodies, and the need for innovative immunogen designs. Collaborative efforts and novel approaches are imperative for advancing vaccine research.

B cell immunotherapy represents a promising frontier in HIV management, ranging from monoclonal antibodies to B cell engineering. These innovative approaches offer potential avenues for therapeutic intervention and highlight the dynamic nature of research in the pursuit of effective

treatments. The delicate balance between immune activation and dysfunction, CD4+ T cell depletion, and chronic inflammation defines the immunopathogenesis of HIV. Achieving a nuanced understanding of this balancing act is essential for optimizing therapeutic interventions and moving toward a functional cure. Persistent challenges, including viral persistence, vaccine development hurdles, and healthcare disparities, underscore the need for ongoing research and innovation. Future directions should prioritize individualized therapies, global access to treatment, technological integration, and comprehensive approaches to address the multifaceted aspects of HIV.

References

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-9.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health

Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.

19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-34. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
25. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-42.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-34.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-4.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-83.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
35. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-11. http://research.sdpublishers.net/id/eprint/2819/.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-8.
38. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
40. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
41. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
42. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
43. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-48.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
44. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
45. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

46. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-10. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
51. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/Ii1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-9.
63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
64. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
69. Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
74. Upton J. Immunodeficiencies with hypergammaglobulinemia: a review. LymphoSign Journal. 2014;2(2):57-73.
75. Moir S, Fauci AS. B-cell responses to HIV infection. Immunological reviews. 2017;275(1):33-48.
76. Nagase H, Agematsu K, Kitano K, Takamoto M, Okubo Y, Komiyama A, Sugane K. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clinical immunology. 2001;100(2):250-259.
77. Patel EU, Gianella S, Newell K, Tobian AA, Kirkpatrick AR, Nalugoda F, Grabowski MK, Gray RH, Serwadda D, Quinn TC, Redd AD. Elevated cytomegalovirus IgG antibody levels are associated with HIV-1 disease progression and immune activation. Aids. 2017;31(6):807-813.
78. Abdurakhmanov A, Zandman-Goddard G. HIV Spectrum and autoimmune diseases. InInfection and Autoimmunity 2015: 371-392. Academic Press.
79. Cooper L, Good-Jacobson KL. Dysregulation of humoral immunity in chronic infection. Immunology and cell biology. 2020;98(6):456-66.
80. Taubert R, Engel B, Diestelhorst J, Hupa-Breier KL, Behrendt P, Baerlecken NT, Sühs KW, Janik MK, Zachou K, Sebode M, Schramm C. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology. 2022;75(1):13-27.
81. Haas A, Zimmermann K, Oxenius A. Antigen-dependent and-independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. Journal of virology. 2011;85(23):12102-13.
82. Abaza A, Idris FS, Shaikh HA, Vahora I, Moparthi KP, Al Rushaidi MT, Muddam MR, Obajeun OA, Jaramillo AP, Khan S, Muddam M. Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics. Cureus. 2023;15(9).
83. Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. Science. 2013;341(6151):1205-11.
84. Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunological reviews. 2019;292(1):149-63.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15

85. Sacco KA, Abraham RS. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;10(8):713-28.
86. Klasse PJ, Sanders RW, Cerutti A, Moore JP. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Research and Human Retroviruses. 2012;28(1):1-5.
87. Lukacs NW, Malinczak CA. Harnessing cellular immunity for vaccination against respiratory viruses. Vaccines. 2020;8(4):783.
88. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a cause of immune activation and immunosenescence. Mediators of inflammation. 2017.
89. Kelesidis T, Papakonstantinou V, Detopoulou P, Fragopoulou E, Chini M, Lazanas MC, Antonopoulou S. The role of platelet-activating factor in chronic inflammation, immune activation, and comorbidities associated with HIV infection. AIDS reviews. 2015;17(4):191.

Citation: Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15